Local versus Systemic Therapy for Noninfectious Uveitis (NIU).

Area of Science:

• Ophthalmology
• Immunology
• Pharmacology

Background:

• Noninfectious uveitis (NIU) is a group of inflammatory eye diseases primarily managed with immunosuppressant therapy.
• Recent decades have seen significant pharmaceutical advancements in both localized and systemic treatment modalities for NIU.
• Understanding the evolving therapeutic landscape is crucial for optimizing patient outcomes in NIU management.

Approach:

• This review synthesizes current literature on established and emerging treatments for noninfectious uveitis.
• It critically analyzes the risk-benefit profiles of various therapeutic agents, including steroids, antimetabolites, and biologics.
• The discussion encompasses localized (topical, intravitreal, periocular) and systemic administration routes.

Key Points:

• Established therapies include corticosteroids, antimetabolites, T-cell inhibitors, anti-CD20 agents, IL-6 inhibitors, alkylating agents, and IV immunoglobulin.
• Novel pharmaceutical developments are expanding treatment options for refractory or severe cases of NIU.
• Risk-benefit assessment is essential for tailoring treatment strategies to individual patient needs and disease characteristics.

Conclusions:

• The treatment of noninfectious uveitis has evolved significantly, offering a wider array of effective immunosuppressive options.
• Continued research into novel therapies and careful evaluation of existing ones are vital for improving NIU management.
• Personalized treatment approaches considering efficacy, safety, and patient-specific factors are paramount.